Figure 1: Reaching a crossroads with legacy LIMS<\/strong><\/p>\n Source: Global biotech<\/em><\/p>\n Although the system was feature-rich, adoption soon stalled at just five percent usage of the available features. This was despite abundant training to help users master a steep learning curve. \u201cBut in practice, they couldn\u2019t figure out how to use some of the features in the existing architecture such as the training module, or document management,\u201d explains the director. As a result, manual processes persisted, introducing more paper and complexity. \u201cWe could only make incremental improvements toward automation.\u201d<\/p>\n After receiving health authority (HA) approvals, the team realized continuing with its legacy LIMS would jeopardize its growth ambitions: the system couldn\u2019t adequately support rapid product expansion or global launches. \u201cThe first signs of trouble were when we were trying to scale operations. We didn\u2019t have the resources to manage changes in the system,\u201d adds the director.<\/p>\n The company chose not to delay its transition and started evaluating alternative solutions that would help it scale during commercialization. \u201cWe wanted a modern system to streamline workflows, data control, and improve efficiency,\u201d she says.<\/p>\n The company was already familiar with the Veeva ecosystem, through its Veeva Quality applications (QualityDocs, Training, and QMS) as well as clinical (Veeva eTMF) and regulatory (Veeva RIM). Knowing how easily these applications integrated into its processes (and could facilitate content and data sharing), the team felt confident Veeva LIMS would be a natural fit [Figure 2]<\/strong>.<\/p>\n Figure 2: Choosing modernized QC<\/strong><\/p>\n Source: Global biotech<\/em><\/p>\n Disrupting the status quo can trigger emotional resistance. Often, it is justified. The team had invested \u201cblood, sweat, and tears\u201d into implementing the old system yet faced the prospect of a new LIMS just three years later.<\/p>\n Instead of seeking harmony, the director recommends embracing team emotions and understanding the objections. Many end-users will have valid concerns that the business case should acknowledge and address. Inviting them to join demos puts the onus on your technology partner to prove their worth, as skeptics ask the toughest questions and will be among the most difficult to impress. After the second demo of Veeva LIMS, she remembers receiving a message from a key stakeholder saying, \u201cThis looks annoyingly good\u201d, reinforcing confidence in the decision to switch.<\/p>\n Every business case will balance expected long-term value against cost considerations. However, it\u2019s also worth calculating ROI within a shorter timeframe: for example, the additional capacity your business would gain within the next year if you switched versus the incremental returns of sticking with the existing system. The results may surprise you. The director points out, \u201cWe saw a higher projected ROI with Veeva LIMS than for the legacy system.\u201d<\/p>\n Once the team evaluated Veeva LIMS more closely, a key differentiator was that it could incorporate the solution into its workflows without any disruption. Quality and regulatory professionals would keep accessing certificates of analysis (CoA) in the same way as before, ensuring operational continuity while the company upgraded. \u201cJaws were literally dropping as we saw how smooth the transition would be for something like CoA,\u201d she remembers.<\/p>\n With commercialization just around the corner, a quick transition was critical. Veeva LIMS is designed specifically for pharmaceutical manufacturing, so the teams agreed to a streamlined seven-month implementation leveraging industry-standard best practices. This allowed the team to access additional capabilities quickly and support rapid user adoption. Veeva\u2019s lifecycle development is \u201crapid and reassuring\u201d, so the biotech knew it would benefit from new features further down the line without enduring onerous system upgrades.<\/p>\n To stay on schedule and realize these gains requires good visibility of technical capabilities and the expected implementation support. The team focused on new feature releases that would reduce data silos (such as batch release testing and stability study management). As customization is contrary to the company\u2019s business model, Veeva LIMS is being configured to these specific lab needs, avoiding the prospect of a large IT footprint or heavy system maintenance.<\/p>\n Skilled resources will reduce their time and effort on manual data entry, forms, and other routine tasks to focus on more impactful activities. Automating workflows will reduce the risk of errors and increase right first time, as well as lower the total cost of ownership (TCO). As she notes, \u201cWe are investing in a solution that will support our long-term goals.\u201d<\/p>\n Now in the final stage of its implementation journey, the director credits clear and open communication within the extended project team for solid progress to date. \u201cYou should question what you did previously, whether you\u2019re trying to keep things the same \u2014 and why,\u201d she advises.<\/p>\n Breaking the status quo requires bravery, readiness to embrace other people\u2019s emotions, and refusal to take \u2018no\u2019 for an answer. She concludes, \u201cOur decision to move to Veeva LIMS was driven by practical and emotional factors. We\u2019ve now made a choice that we think will position us for future success.\u201d<\/p>\n![\"\"](\"\/wp-content\/uploads\/2025\/02\/Breaking-the-Status-Quo-and-Embracing-the-Redefinition-of-LIMS_Figure-1.png\")
<\/p>\nMaking a head-and-heart decision<\/h2>\n
![\"\"](\"\/wp-content\/uploads\/2025\/02\/Breaking-the-Status-Quo-and-Embracing-the-Redefinition-of-LIMS_Figure-2.png\")
<\/p>\nA quick and smooth transition<\/h2>\n
Adopting a critical mindset<\/h3>\n